Active targeting with particulate drug carriers in tumor therapy: Fundamentals and recent progress

Fabrizio Marcucci, François Lefoulon

Research output: Contribution to journalArticle

184 Citations (Scopus)

Abstract

Drug therapy for the treatment of tumors is often limited by a narrow therapeutic index. One approach that overcomes this limitation is the active targeting of tumors with particulate drug carriers. The derivatization of particulate drug carriers with a ligand leads to the selective targeting of the particulate to selected cells, thereby focusing drug delivery. In addition, particulate drug carriers have a high loading capacity, do not need covalent conjugation of the drug and the formulation protects the entrapped drug from enzymatic inactivation. Despite these favorable properties, their therapeutic efficacy in animal models has been reported only in recent years. The use of internalizing ligands and the targeting of intravascular tumor cells and endothelial cells of tumor blood vessels have been instrumental in demonstrating the clinical effectiveness of particulate drug carriers in animal models. As a result, several actively targeted particulate carriers have now entered, or are about to enter, clinical investigation. Recent findings, for example, the identification of cell-penetrating peptides with restricted cell selectivity, suggest that further improvements in this approach are likely in the near future.

Original languageEnglish
Pages (from-to)219-228
Number of pages10
JournalDrug Discovery Today
Volume9
Issue number5
DOIs
Publication statusPublished - Mar 1 2004

Fingerprint

Drug Carriers
Neoplasms
Animal Models
Cell-Penetrating Peptides
Vascular Tissue Neoplasms
Ligands
Drug Compounding
Therapeutics
Pharmaceutical Preparations
Endothelial Cells
Drug Therapy

Keywords

  • Active targeting
  • Cancer biology
  • Drug delivery
  • Drug Discovery
  • Immunogenicity
  • In vivo
  • Internalization
  • Molecular Medicine
  • Multivalency
  • Particles
  • Passive targeting
  • Tumor therapy

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Active targeting with particulate drug carriers in tumor therapy : Fundamentals and recent progress. / Marcucci, Fabrizio; Lefoulon, François.

In: Drug Discovery Today, Vol. 9, No. 5, 01.03.2004, p. 219-228.

Research output: Contribution to journalArticle

Marcucci, Fabrizio ; Lefoulon, François. / Active targeting with particulate drug carriers in tumor therapy : Fundamentals and recent progress. In: Drug Discovery Today. 2004 ; Vol. 9, No. 5. pp. 219-228.
@article{f642286356144d20858d89077bfb6257,
title = "Active targeting with particulate drug carriers in tumor therapy: Fundamentals and recent progress",
abstract = "Drug therapy for the treatment of tumors is often limited by a narrow therapeutic index. One approach that overcomes this limitation is the active targeting of tumors with particulate drug carriers. The derivatization of particulate drug carriers with a ligand leads to the selective targeting of the particulate to selected cells, thereby focusing drug delivery. In addition, particulate drug carriers have a high loading capacity, do not need covalent conjugation of the drug and the formulation protects the entrapped drug from enzymatic inactivation. Despite these favorable properties, their therapeutic efficacy in animal models has been reported only in recent years. The use of internalizing ligands and the targeting of intravascular tumor cells and endothelial cells of tumor blood vessels have been instrumental in demonstrating the clinical effectiveness of particulate drug carriers in animal models. As a result, several actively targeted particulate carriers have now entered, or are about to enter, clinical investigation. Recent findings, for example, the identification of cell-penetrating peptides with restricted cell selectivity, suggest that further improvements in this approach are likely in the near future.",
keywords = "Active targeting, Cancer biology, Drug delivery, Drug Discovery, Immunogenicity, In vivo, Internalization, Molecular Medicine, Multivalency, Particles, Passive targeting, Tumor therapy",
author = "Fabrizio Marcucci and Fran{\cc}ois Lefoulon",
year = "2004",
month = "3",
day = "1",
doi = "10.1016/S1359-6446(03)02988-X",
language = "English",
volume = "9",
pages = "219--228",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Active targeting with particulate drug carriers in tumor therapy

T2 - Fundamentals and recent progress

AU - Marcucci, Fabrizio

AU - Lefoulon, François

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Drug therapy for the treatment of tumors is often limited by a narrow therapeutic index. One approach that overcomes this limitation is the active targeting of tumors with particulate drug carriers. The derivatization of particulate drug carriers with a ligand leads to the selective targeting of the particulate to selected cells, thereby focusing drug delivery. In addition, particulate drug carriers have a high loading capacity, do not need covalent conjugation of the drug and the formulation protects the entrapped drug from enzymatic inactivation. Despite these favorable properties, their therapeutic efficacy in animal models has been reported only in recent years. The use of internalizing ligands and the targeting of intravascular tumor cells and endothelial cells of tumor blood vessels have been instrumental in demonstrating the clinical effectiveness of particulate drug carriers in animal models. As a result, several actively targeted particulate carriers have now entered, or are about to enter, clinical investigation. Recent findings, for example, the identification of cell-penetrating peptides with restricted cell selectivity, suggest that further improvements in this approach are likely in the near future.

AB - Drug therapy for the treatment of tumors is often limited by a narrow therapeutic index. One approach that overcomes this limitation is the active targeting of tumors with particulate drug carriers. The derivatization of particulate drug carriers with a ligand leads to the selective targeting of the particulate to selected cells, thereby focusing drug delivery. In addition, particulate drug carriers have a high loading capacity, do not need covalent conjugation of the drug and the formulation protects the entrapped drug from enzymatic inactivation. Despite these favorable properties, their therapeutic efficacy in animal models has been reported only in recent years. The use of internalizing ligands and the targeting of intravascular tumor cells and endothelial cells of tumor blood vessels have been instrumental in demonstrating the clinical effectiveness of particulate drug carriers in animal models. As a result, several actively targeted particulate carriers have now entered, or are about to enter, clinical investigation. Recent findings, for example, the identification of cell-penetrating peptides with restricted cell selectivity, suggest that further improvements in this approach are likely in the near future.

KW - Active targeting

KW - Cancer biology

KW - Drug delivery

KW - Drug Discovery

KW - Immunogenicity

KW - In vivo

KW - Internalization

KW - Molecular Medicine

KW - Multivalency

KW - Particles

KW - Passive targeting

KW - Tumor therapy

UR - http://www.scopus.com/inward/record.url?scp=1242271302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242271302&partnerID=8YFLogxK

U2 - 10.1016/S1359-6446(03)02988-X

DO - 10.1016/S1359-6446(03)02988-X

M3 - Article

C2 - 14980540

AN - SCOPUS:1242271302

VL - 9

SP - 219

EP - 228

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 5

ER -